Thermo Fisher secures EUA for 2 new COVID-19 tests

By LabPulse.com staff writers

August 16, 2021 -- The U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Thermo Fisher Scientific for two new COVID-19 tests, TaqPath COVID-19 Fast PCR Combo Kit 2.0 and TaqPath COVID-19 RNase P Combo Kit 2.0.

The Thermo Fisher tests are intended to address emerging mutations and variants, the company said. Both target eight genes across three regions of SARS-CoV-2.

TaqPath COVID-19 Fast PCR Combo Kit 2.0 tests saliva samples, while TaqPath COVID-19 RNase P Combo Kit 2.0 tests nasal samples, according to Thermo Fisher.

Thermo Fisher announces new suite of assays
Thermo Fisher Scientific announced a new suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T cells...
Thermo Fisher expands leadership team
Thermo Fisher Scientific announced it is promoting from within for its newly created chief medical officer position.
Ortho inks deal with Thermo Fisher for QA software
Ortho Clinical Diagnostics has signed a distribution deal with Thermo Fisher Scientific for its quality assurance (QA) software. The companies said the...
Thermo Fisher announces Q1 revenue increase
Thermo Fisher Scientific said that its efforts to help scale vaccine production and support diagnostic testing globally during the COVID-19 pandemic were...
Thermo Fisher to launch new qPCR system
Thermo Fisher Scientific announced it has completed a U.S. Food and Drug Administration listing to launch its Applied Biosystems QuantStudio 5 Dx real-time...

Copyright © 2021 LabPulse.com

Last Updated np 8/16/2021 6:28:29 PM